PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29101083-0	2017	Draft genome sequence of a tigecycline-resistant KPC-2-producing Klebsiella pneumoniae ST15 clinical isolate from China.	Tigecycline	27-38	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	49-54	
35572689-0	2022	Emergence of a Hypervirulent Tigecycline-Resistant Klebsiella pneumoniae Strain Co-producing bla NDM-1 and bla KPC-2 With an Uncommon Sequence Type ST464 in Southwestern China.	Tigecycline	29-40	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	111-116	
35038616-0	2022	Evolution of tet(A) Variant Mediating Tigecycline Resistance in KPC-2-Producing Klebsiella pneumoniae during Tigecycline Treatment.	Tigecycline	38-49	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	64-69	
35038616-0	2022	Evolution of tet(A) Variant Mediating Tigecycline Resistance in KPC-2-Producing Klebsiella pneumoniae during Tigecycline Treatment.	Tigecycline	109-120	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	64-69	
29101083-3	2017	Here we report the draft genome sequence of a clinical tigecycline-resistant KPC-2-producing K. pneumoniae isolate (TRKP1).	Tigecycline	55-66	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	77-82	
25801560-0	2015	In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials.	Tigecycline	62-73	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	82-87	
22016687-5	2011	The KPC-2-producing isolate was resistant to all tested beta-lactams (including imipenem and meropenem), amikacin, tobramycin, ciprofloxacin, levofloxacin, and trimethoprim-sulfamethoxazole, but was susceptible to gentamicin, colistin, polymyxin B, and tigecycline.	Tigecycline	253-264	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	4-9